Introduction: Despite significant advances in treatment and prevention, graft-versus-host disease (GVHD) still represents the main cause of morbidity and mortality after allogeneic hematopoietic stem cell transplantation. Thus, considerable research efforts have been made to find and validate reliable biomarkers for diagnosis, prognosis, and risk stratification of GVHD. Areas covered: In this review the most recent evidences on different types of biomarkers studied for GVHD, such as genetic, plasmatic, cellular markers, and those associated with microbiome, were summarized. A comprehensive search of peer-review literature was performed in PubMed including meta-analysis, preclinical and clinical trials, using the terms: cellular and plasma biomarkers, graft-versus-host disease, cytokines, and allogeneic hematopoietic stem cell transplantation. Expert opinion: In the near future, several validated biomarkers will be available to help clinicians in the diagnosis of GVHD, the identification of patients at high risk of GVHD development and in patients' stratification according to its severity. Then, immunosuppressive treatment could be tailored to each patient's real needs. However, more efforts are needed to achieve this goal. Although most of the proposed biomarkers currently lack validation with large-scale clinical data, their study led to improved knowledge of the biological basis of GVHD, and ultimately to implementation of GHVD treatment.

Biomarkers for acute and chronic graft versus host disease: state of the art / L. Giaccone, D.G. Faraci, S. Butera, G. Lia, C. Di Vito, G. Gabrielli, M. Cerrano, J. Mariotti, C. Dellacasa, F. Felicetti, E. Brignardello, D. Mavilio, B. Bruno. - In: EXPERT REVIEW OF HEMATOLOGY. - ISSN 1747-4086. - 14:1(2021), pp. 79-96. [10.1080/17474086.2021.1860001]

Biomarkers for acute and chronic graft versus host disease: state of the art

G. Lia
Membro del Collaboration Group
;
C. Di Vito
Membro del Collaboration Group
;
J. Mariotti
Membro del Collaboration Group
;
D. Mavilio
Penultimo
;
2021

Abstract

Introduction: Despite significant advances in treatment and prevention, graft-versus-host disease (GVHD) still represents the main cause of morbidity and mortality after allogeneic hematopoietic stem cell transplantation. Thus, considerable research efforts have been made to find and validate reliable biomarkers for diagnosis, prognosis, and risk stratification of GVHD. Areas covered: In this review the most recent evidences on different types of biomarkers studied for GVHD, such as genetic, plasmatic, cellular markers, and those associated with microbiome, were summarized. A comprehensive search of peer-review literature was performed in PubMed including meta-analysis, preclinical and clinical trials, using the terms: cellular and plasma biomarkers, graft-versus-host disease, cytokines, and allogeneic hematopoietic stem cell transplantation. Expert opinion: In the near future, several validated biomarkers will be available to help clinicians in the diagnosis of GVHD, the identification of patients at high risk of GVHD development and in patients' stratification according to its severity. Then, immunosuppressive treatment could be tailored to each patient's real needs. However, more efforts are needed to achieve this goal. Although most of the proposed biomarkers currently lack validation with large-scale clinical data, their study led to improved knowledge of the biological basis of GVHD, and ultimately to implementation of GHVD treatment.
Circulating endothelial cells; Cytokines; Extracellular vesicles; Graft-versus-host disease; Microbiome; Natural killer; Proteomics; Regulatory T-cells; SNPs; microRNA
Settore MED/46 - Scienze Tecniche di Medicina di Laboratorio
Settore MED/04 - Patologia Generale
Settore MED/06 - Oncologia Medica
Settore MED/15 - Malattie del Sangue
2021
24-dic-2020
Article (author)
File in questo prodotto:
File Dimensione Formato  
I:Giaccone L. et al. - Expert Review of Haematology.pdf

Open Access dal 25/12/2021

Tipologia: Post-print, accepted manuscript ecc. (versione accettata dall'editore)
Dimensione 14.63 MB
Formato Adobe PDF
14.63 MB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/798454
Citazioni
  • ???jsp.display-item.citation.pmc??? 8
  • Scopus 12
  • ???jsp.display-item.citation.isi??? 10
social impact